Shares in this article
The so-called Foundationone CDX test is the first diagnostic test accompanying therapy to identify patients with neurotrophic receptor tyrosine kinase gene fusion, for whom Vitrakvi would be a suitable therapy option, according to the DAX group. It is a CGP test that is now approved for all solid tumors and thus enables broader access to biomarker tests in oncology.
“We look forward to continuing our global collaboration with Foundation Medicine to give cancer patients better access to biomarker tests and to identify the right treatment option for them,” said Robert LaCaze, head of Bayer’s Oncology Strategic Business Unit.
Vitrakvi with the active ingredient larotrectin is a drug that can be used to treat malignant tumors that are caused by a gene mutation. The agent blocks a fusion protein that acts as a driver. Unlike other cancer drugs, its use is therefore not restricted to a specific organ. However, this cause of cancer is quite rare. Only about one percent of all cases have a fusion protein in which one of the three NTRK genes is involved. A molecular genetic test must be used to determine whether the agent is suitable for a patient in a specific case. In addition to Foundation Medicine, Bayer also works with other test providers such as ArcherDX and Illumina.
FRANKFURT (Dow Jones)
Current certificates from
More news about Bayer
Image Sources: 360b / Shutterstock.com